Search for: "Novartis International AG"
Results 21 - 40
of 120
Sort by Relevance
|
Sort by Date
17 Jun 2020, 1:15 pm
From this June 12, 2020 news article, "Beovu Labeling Updated With Additional Safety Information", we get the following details: The update is based on a recent internal review conducted by Novartis of adverse events observed in the HAWK & HARRIER clinical trials, including rare postmarketing safety reports of vasculitis. [read post]
27 Feb 2020, 12:40 pm
Beovu injections were approved by the FDA in October 2019 to treat wet age-related macular degeneration, a condition that can eventually lead to blindness. [read post]
31 Dec 2019, 3:58 am
In one case, Novartis AG, a Swiss pharmaceutical company, developed “Glivec”, an anti-cancer drug. [read post]
3 Jul 2019, 11:02 am
Barbara Levi Mager is a longtime in-house leader for Swiss pharmaceutical company Novartis International AG and Sandoz, a division of Novartis. [read post]
22 Jun 2019, 9:15 am
The landmark judgment of the Supreme Court of India in Novartis AG & Ors. .v. [read post]
22 Jun 2019, 9:15 am
The landmark judgment of the Supreme Court of India in Novartis AG & Ors. .v. [read post]
30 Apr 2019, 7:22 am
Final panellist Jürgen Dressel (ex- Novartis Pharma AG) explained that, going back to basics, the SPC is meant to be a reward for R&D and there should be legal certainty and a harmonised situation for the international market. [read post]
30 Apr 2019, 5:29 am
Jürgen Dressel (ex- Novartis Pharma AG) further commented that of course there is the further issue in Germany that invalidity proceedings cannot even be commenced whilst EPO opposition proceeding are ongoing. [read post]
28 Apr 2019, 8:20 am
In the Rituximab case (District Court of Munich, May 2017), the court said that the generic case law stipulating that the balance of interests in principle favors the originator cannot be applied to biosimilar situations and that a full assessment of the specific circumstances is required in each case.From the audience Jürgen Dressel (ex-Novartis Pharma AG, Basel) asked about the uptake of biosimilars and whether costs will decrease the more medicines healthcare systems… [read post]
13 Apr 2019, 12:25 pm
AG Szpunar thinks not necessarily | The CNY 260 million fine on QVOD is final! [read post]
6 Apr 2019, 9:46 am
AG Szpunar thinks not necessarily | The CNY 260 million fine on QVOD is final! [read post]
27 Mar 2019, 11:33 am
AG Szpunar thinks not necessarily | The CNY 260 million fine on QVOD is final! [read post]
24 Mar 2019, 3:26 pm
AG Szpunar thinks not necessarily | The CNY 260 million fine on QVOD is final! [read post]
29 Jun 2018, 7:50 am
AG (318 F.3d 1081, 1098 (Fed. [read post]
25 Jun 2018, 3:49 am
Starting from 2009, when the Supreme Commercial Court restrained a generic drug for the first time (Novartis AG vs. [read post]
1 Dec 2017, 11:35 am
Big pharma players such as Eli Lilly, Novo Nordisk and Allergan are committed to voluntary price restraints, while companies such as Novartis and Roche are in favor of value-based pricing. [read post]
12 Apr 2017, 9:52 am
Patent No.8,324,283 (the ’283 patent), owned by Novartis AG andMistubishi Tanabe Pharma Corp. [read post]
5 Apr 2017, 9:08 am
Novartis AG (Noven IV), No. [read post]
4 Dec 2015, 2:55 am
Novartis AG & Novartis GmbH regarding the validity and (in)direct infringement of EP 0296 689, Novartis’ Swiss type 2nd medical use patent covering the use of zoledronate in the preparation of a medicament for the treatment of osteoporosis. [read post]
3 Nov 2015, 12:13 pm
Novartis AG, a European based pharmaceutical company, agreed to settle a False Claims Act (FCA) lawsuit for $390 million, a week before the original $3.3 billion FCA lawsuit was set to go to trial on November 2, 2015. [read post]
